Triptolide: structural modifications, structure–activity relationships, bioactivities, clinical development and mechanisms
ZL Zhou, YX Yang, J Ding, YC Li, ZH Miao - Natural product reports, 2012 - pubs.rsc.org
Covering: 1972 to 2011 Triptolide, a principal bioactive ingredient of Tripterygium wilfordii
Hook F, has attracted extensive exploration due to its unique structure of a diterpenoid …
Hook F, has attracted extensive exploration due to its unique structure of a diterpenoid …
[HTML][HTML] Phytochemicals for the prevention and treatment of renal cell carcinoma: preclinical and clinical evidence and molecular mechanisms
EM Bajalia, FB Azzouz, DA Chism, DM Giansiracusa… - Cancers, 2022 - mdpi.com
Simple Summary Renal cell carcinoma (RCC) is the most frequently diagnosed kidney
cancer. Once RCC metastasizes, successful treatment is difficult to achieve. There is an …
cancer. Once RCC metastasizes, successful treatment is difficult to achieve. There is an …
Enhanced photothermal therapy through the in situ activation of a temperature and redox dual‐sensitive nanoreservoir of triptolide
Photothermal therapy (PTT) has attracted tremendous attention due to its noninvasiveness
and localized treatment advantages. However, heat shock proteins (HSPs) associated self …
and localized treatment advantages. However, heat shock proteins (HSPs) associated self …
[HTML][HTML] Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways
J Li, X Liang, X Yang - Oncology reports, 2012 - spandidos-publications.com
Pancreatic cancer is one of the most deadly carcinomas worldwide. Although gemcitabine
as the standard chemotherapy agent has been proven to be effective, the response rate …
as the standard chemotherapy agent has been proven to be effective, the response rate …
[HTML][HTML] Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells
F Zhao, W Huang, Z Zhang, L Mao, Y Han, J Yan… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Triptolide, an active compound extracted from the Chinese herb thunder god vine
(Tripterygium wilfordii Hook F.), has potent anti-tumor activity. Recently, triptolide was found …
(Tripterygium wilfordii Hook F.), has potent anti-tumor activity. Recently, triptolide was found …
Triptolide with potential medicinal value for diseases of the central nervous system
Y Zheng, WJ Zhang, XM Wang - CNS neuroscience & …, 2013 - Wiley Online Library
Tripterygium wilfordii Hook. f.(TWHF) has a long history as a T raditional C hinese M edicine
(TCM) herb that aids in treating inflammatory and autoimmune diseases. The major …
(TCM) herb that aids in treating inflammatory and autoimmune diseases. The major …
[HTML][HTML] Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin
H Zhao, Z Yang, X Wang, X Zhang, M Wang… - … & molecular medicine, 2012 - nature.com
Triptolide, a compound extracted from the traditional Chinese medicine preparation of
Tripterygium wilfordii Hook F., has been reported to have anti-inflammatory and anti-cancer …
Tripterygium wilfordii Hook F., has been reported to have anti-inflammatory and anti-cancer …
Gene expression profiling and pathway analysis of hepatotoxicity induced by triptolide in Wistar rats
J Wang, Z Jiang, J Ji, X Wang, T Wang, Y Zhang… - Food and Chemical …, 2013 - Elsevier
Triptolide (TP), a major component of TWHF, is widely used to treat rheumatoid arthritis,
systemic lupus erythematosus, nephritis and leprosy. However, its clinical use is limited by …
systemic lupus erythematosus, nephritis and leprosy. However, its clinical use is limited by …
Preclinical pharmacokinetics of triptolide: a potential antitumor drug
W Song, M Liu, J Wu, H Zhai, Y Chen… - Current drug …, 2019 - ingentaconnect.com
Background: Triptolide, a bioactive component in Tripterygium wilfordii extracts, possess
strong antiproliferative activity on all 60-National Cancer Institute (NCI) cancer cell lines …
strong antiproliferative activity on all 60-National Cancer Institute (NCI) cancer cell lines …
[HTML][HTML] HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
E Juengel, S Nowaz, J Makarevi, I Natsheh, I Werner… - Molecular cancer, 2014 - Springer
Background Targeted therapies have improved therapeutic options of treating renal cell
carcinoma (RCC). However, drug response is temporary due to resistance development …
carcinoma (RCC). However, drug response is temporary due to resistance development …